机译:妊娠预防乙型肝炎病毒传播的持续时间短:缺乏效力和抗性突变选择
Research and Molecular Development Victorian Infectious Diseases Reference Laboratory WHO;
Research and Molecular Development Victorian Infectious Diseases Reference Laboratory WHO;
Research and Molecular Development Victorian Infectious Diseases Reference Laboratory WHO;
Liverpool Hospital South West Area Health ServiceSydney NSW Australia;
Liverpool Hospital South West Area Health ServiceSydney NSW Australia;
Liverpool Hospital South West Area Health ServiceSydney NSW Australia;
Genematrix Inc.Seongnam Seoul South Korea;
Genematrix Inc.Seongnam Seoul South Korea;
Genematrix Inc.Seongnam Seoul South Korea;
Lowi Cancer Research Centre University of New South WalesSydney NSW Australia;
Research and Molecular Development Victorian Infectious Diseases Reference Laboratory WHO;
Research and Molecular Development Victorian Infectious Diseases Reference Laboratory WHO;
Liverpool Hospital South West Area Health ServiceSydney NSW Australia;
Research and Molecular Development Victorian Infectious Diseases Reference Laboratory WHO;
hepatitis B virus; lamivudine in pregnancy; primary drug resistance; ultra-deep pyrosequencing;
机译:拉米夫定在孕妇中预防乙型肝炎病毒传播的短期持续时间:效力不足和耐药性突变的选择
机译:接受抗逆转录病毒预防以预防马拉维母婴传播的孕妇HBV和HIV感染的拉米夫定耐药性乙型肝炎病毒突变的出现
机译:简短交流:在新诊断的HIV个体中传播具有拉米夫定耐药性突变的乙肝病毒。
机译:在针对中和抗体反应的免疫逃逸情况下丙型肝炎病毒的共同进化突变-分析病毒基因组共同进化突变的生物信息学工作流程
机译:HCC相关突变对乙型肝炎病毒的功能研究。
机译:通过线探针分析评估长期接受拉米夫定治疗的慢性乙型肝炎病毒感染患者的主要和代偿性拉米夫定耐药性突变的演变
机译:接受抗逆转录病毒预防以预防马拉维母婴传播的孕妇感染了HBV和HIV的拉米夫定耐药性B型肝炎病毒突变的出现